Therapeutic Approach

Archive: August, 2018

Ritter Pharmaceuticals to Present at 20th Annual HC Wainwright Global Investment Conference on September 5, 2018

LOS ANGELES, Aug 28, 2018 (GLOBE NEWSWIRE) — Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of novel therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases with an initial focus on the development of RP-G28, a drug candidate with the potential to be the first FDA-approved treatment for […]

Leave Your Comments »

Ritter Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2018 and Recent Progress

LOS ANGELES (August 14, 2018) – Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of novel therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases with an initial focus on the development of RP-G28, a drug candidate with the potential to be the first FDA-approved treatment for lactose intolerance, […]

Leave Your Comments »

Featuring Recent Posts WordPress Widget development by YD